Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HOWL

Werewolf Therapeutics Inc

May 26 • 04:00PM ET

0.4631

+0.0195 4.40 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: XLO CADL BCAB ATRA INAB

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.21	Insider Own	14.59%	Shs Outstand	48.60M	Perf Week	-6.50%
Market Cap	22.51M	Forward P/E	-	EPS next Y	-	Insider Trans	-34.19%	Shs Float	41.51M	Perf Month	-43.04%
Enterprise Value	13.71M	PEG	-	EPS next Q	-	Inst Own	25.61%	Short Float	1.75%	Perf Quarter	-30.00%
Income	-56.27M	P/S	-	EPS this Y	-	Inst Trans	-2.45%	Short Ratio	1.52	Perf Half Y	-45.82%
Sales	0.00M	P/B	1.84	EPS next Y	-	ROA	-68.09%	Short Interest	0.73M	Perf YTD	-26.90%
Book/sh	0.25	P/C	0.48	EPS next 5Y	-	ROE	-161.89%	52W High	2.38 -80.54%	Perf Year	-59.73%
Cash/sh	0.96	P/FCF	-	EPS past 3/5Y	10.71% -6.15%	ROIC	-289.76%	52W Low	0.40 14.63%	Perf 3Y	-83.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.97% 12.75%	Perf 5Y	-96.39%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	26.30%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.27	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	31.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.27	EPS Q/Q	29.71%	SMA20	-21.49%	Beta	0.33	Target Price	4.00
Payout	-	Debt/Eq	3.09	Sales Q/Q	-	SMA50	-39.43%	Rel Volume	1.67	Prev Close	0.44
Employees	39	LT Debt/Eq	0.59	Earnings	May 07 AMC	SMA200	-54.22%	Avg Volume	477.10K	Price	0.46
IPO	Apr 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	797,907	Change	4.40%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-25	Downgrade	Wedbush	Outperform → Neutral	$1
Apr-03-24	Initiated	JMP Securities	Mkt Outperform	$12
Aug-24-23	Initiated	Wedbush	Outperform	$9
Jun-06-23	Resumed	Jefferies	Buy	$11 → $12
Sep-10-21	Initiated	BofA Securities	Buy	$26
May-25-21	Initiated	SVB Leerink	Outperform	$29
May-25-21	Initiated	Jefferies	Buy	$22
May-25-21	Initiated	H.C. Wainwright	Buy	$32
May-25-21	Initiated	Evercore ISI	Outperform	$23

May-07-26 04:05PM	Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates (GlobeNewswire) +9.68%
Mar-27-26 07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates (GlobeNewswire) -9.54%
Feb-24-26 04:09PM	Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives (GlobeNewswire)
Jan-12-26 04:23AM	Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results (Insider Monkey)
Dec-18-25 08:00AM	Werewolf Therapeutics Announces Pipeline and Business Updates (GlobeNewswire) -39.57%
12:00PM	Loading…
Dec-15-25 12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks) -6.36%
Nov-07-25 09:00AM	Werewolf Therapeutics Presents Data Expanding Its PREDATOR Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
Nov-04-25 07:00AM	Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.63%
Oct-31-25 08:58AM	Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake (Zacks) -6.43%
Oct-29-25 01:45PM	Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised (Zacks)
Oct-28-25 02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
Oct-23-25 02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-08-25 08:00AM	Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer (GlobeNewswire)
Oct-03-25 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire) +6.77%
05:03PM	Loading…
Sep-08-25 05:03PM	Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Sep-02-25 08:00AM	Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 07:00AM	Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-13-25 08:55AM	XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates (Zacks) +12.50%
Aug-12-25 05:35PM	Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Aug-07-25 08:25AM	CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-29-25 12:30PM	ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer (Exec Edge)
Jul-09-25 08:00AM	Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit (GlobeNewswire)
Jun-12-25 08:00AM	Werewolf Therapeutics to Participate in the BIO International Convention (GlobeNewswire)
May-29-25 12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks)
08:00AM	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 (GlobeNewswire) -5.26%
May-13-25 08:00AM	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
May-08-25 07:00AM	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.54%
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:05AM	Loading…
May-05-25 08:05AM	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire)
08:00AM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer (GlobeNewswire) +8.37%
Mar-31-25 08:00AM	Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.61%
Mar-11-25 07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-25 08:00AM	Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-24-25 07:30AM	Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors (GlobeNewswire)
Jan-14-25 08:35AM	Werewolf Therapeutics provides business update, highlights 2025 outlook (TipRanks)
Jan-13-25 08:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire)
Nov-20-24 08:00AM	Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference (GlobeNewswire)
Nov-07-24 09:02AM	Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) -8.20%
09:00AM	Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 08:00AM	Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases (GlobeNewswire) -5.02%
Oct-20-24 06:04AM	Bank of America Predicts up to ~390% Surge for These 2 Strong Buy Stocks (TipRanks)
Oct-04-24 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.09%
Aug-08-24 08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.19%
07:05AM	Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-25-24 07:00AM	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (GlobeNewswire) -10.34%
Jun-01-24 09:00AM	Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors (GlobeNewswire)
May-30-24 08:00AM	Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.30%
May-23-24 05:00PM	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting (GlobeNewswire) +5.52% -5.43%
May-03-24 01:53PM	HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-24 10:05AM	Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 08:00AM	Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) +5.75%
Apr-15-24 12:00PM	All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy (Zacks) +17.06%
Apr-05-24 04:30PM	Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) -9.12%
Apr-04-24 04:30PM	Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting (GlobeNewswire)
Mar-12-24 09:55AM	How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37% (Zacks)
Mar-07-24 02:52PM	HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:45AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 08:00AM	Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire)
Jan-08-24 07:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire)
Jan-04-24 04:05PM	Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors (GlobeNewswire) +20.69%
Nov-22-23 07:00AM	Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 04:25PM	Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 07:00AM	Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +47.44%
Oct-31-23 09:00AM	Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-27-23 04:58AM	Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength? (Zacks) +6.49%
Sep-27-23 09:00AM	Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +11.00%
Sep-11-23 04:05PM	Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 (GlobeNewswire)
Sep-05-23 04:05PM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 09:57AM	Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls (The Fly) +26.74%
Aug-13-23 08:04AM	Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? (Simply Wall St.)
Aug-11-23 03:21PM	Werewolf Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-10-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-30-23 06:10AM	Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$11m last week but private equity firms profited the most (Simply Wall St.) +5.90%
Jun-01-23 07:00AM	Werewolf Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +14.42%
May-11-23 08:35AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.88%
07:00AM	Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 07:00AM	Werewolf Therapeutics to Participate in May Investor Conferences (GlobeNewswire) +5.49%
Apr-19-23 10:00AM	Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology Research (GlobeNewswire)
Mar-23-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.24%
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-23 07:30AM	UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-15-23 07:30AM	Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023 (GlobeNewswire)
Feb-24-23 07:30AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 (GlobeNewswire) -13.77%
Feb-17-23 05:08AM	Investors in Werewolf Therapeutics (NASDAQ:HOWL) have unfortunately lost 53% over the last year (Simply Wall St.)
Feb-07-23 07:00AM	Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 05:16AM	Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) top owners are private equity firms with 42% stake, while31% is held by institutions (Simply Wall St.) +22.51%
Dec-12-22 10:22AM	Is Werewolf Therapeutics (NASDAQ:HOWL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +7.26%
Nov-10-22 09:00AM	Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE Molecule, at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 04:05PM	Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

FounderDr. Daniel J. Hicklin Ph.D.

VP of FinanceMr. Michael Urban

Chief Business OfficerMr. Steven H. Bloom R.Ph.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EVNIN LUKE	Director	May 22 '26	Sale	0.45	87,425	39,341	831,635	May 26 06:18 PM
EVNIN LUKE	Director	May 26 '26	Sale	0.47	67,950	31,936	763,685	May 26 06:18 PM
EVNIN LUKE	Director	May 21 '26	Sale	0.42	36,387	15,283	919,060	May 26 06:18 PM
EVNIN LUKE	Director	May 20 '26	Sale	0.43	85,895	36,935	955,447	May 20 06:08 PM
EVNIN LUKE	Director	May 19 '26	Sale	0.45	62,970	28,336	1,041,342	May 20 06:08 PM
EVNIN LUKE	Director	May 18 '26	Sale	0.50	22,184	11,092	1,104,312	May 20 06:08 PM
MPM Oncology Innovations Fund,	Shareholder	May 18 '26	Proposed Sale	0.52	63,540	32,729		May 18 05:03 PM
MPM BioVentures 2014, L.P.	Shareholder	May 18 '26	Proposed Sale	0.52	290,419	149,595		May 18 05:02 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	May 18 '26	Proposed Sale	0.52	19,370	9,977		May 18 05:02 PM
UBS Oncology Impact Fund, L.P.	Shareholder	May 18 '26	Proposed Sale	0.52	240,280	123,768		May 18 05:02 PM
MPM Asset Management LLC	Shareholder	May 18 '26	Proposed Sale	0.52	45,998	23,694		May 18 05:01 PM
MPM Asset Management Investors	Shareholder	May 18 '26	Proposed Sale	0.52	9,996	5,149		May 18 05:01 PM
EVNIN LUKE	Director	May 13 '26	Sale	0.54	44,679	24,127	1,126,496	May 13 04:06 PM
EVNIN LUKE	Director	May 08 '26	Sale	0.70	305,741	214,019	1,273,008	May 12 07:47 PM
EVNIN LUKE	Director	May 12 '26	Sale	0.64	67,885	43,446	1,171,175	May 12 07:47 PM
EVNIN LUKE	Director	May 11 '26	Sale	0.67	33,948	22,745	1,239,060	May 12 07:47 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 08 '26	Sale	0.71	376,526	267,333	418,813	May 12 06:26 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 12 '26	Sale	0.64	101,151	64,737	406,282	May 12 06:26 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	May 11 '26	Sale	0.67	87,490	58,618	413,001	May 12 06:26 PM
MPM Oncology Innovations Fund,	Shareholder	May 11 '26	Proposed Sale	0.68	18,485	12,570		May 11 04:33 PM
MPM Asset Management LLC	Shareholder	May 11 '26	Proposed Sale	0.68	13,382	9,100		May 11 04:33 PM
MPM BioVentures 2014, L.P.	Shareholder	May 11 '26	Proposed Sale	0.68	84,491	57,454		May 11 04:32 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	May 11 '26	Proposed Sale	0.68	5,635	3,832		May 11 04:32 PM
UBS Oncology Impact Fund, L.P.	Shareholder	May 11 '26	Proposed Sale	0.68	69,904	47,535		May 11 04:32 PM
MPM Asset Management Investors	Shareholder	May 11 '26	Proposed Sale	0.68	2,908	1,977		May 11 04:31 PM
EVNIN LUKE	Director	May 07 '26	Sale	0.63	79,086	49,824	1,578,749	May 07 06:22 PM
EVNIN LUKE	Director	May 06 '26	Sale	0.66	14,635	9,659	1,657,835	May 07 06:22 PM
EVNIN LUKE	Director	May 05 '26	Sale	0.69	6,860	4,733	1,672,470	May 07 06:22 PM
EVNIN LUKE	Director	Apr 30 '26	Sale	0.72	168,262	121,149	1,785,687	May 04 06:00 PM
EVNIN LUKE	Director	May 01 '26	Sale	0.73	58,394	42,628	1,727,293	May 04 06:00 PM
EVNIN LUKE	Director	May 04 '26	Sale	0.72	47,963	34,533	1,679,330	May 04 06:00 PM
MPM Asset Management Investors	Shareholder	May 01 '26	Proposed Sale	0.72	12,515	9,006		May 01 04:52 PM
UBS Oncology Impact Fund, L.P.	Shareholder	May 01 '26	Proposed Sale	0.72	300,821	216,471		May 01 04:52 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	May 01 '26	Proposed Sale	0.72	24,251	17,451		May 01 04:52 PM
MPM BioVentures 2014, L.P.	Shareholder	May 01 '26	Proposed Sale	0.72	363,593	261,642		May 01 04:51 PM
MPM Oncology Innovations Fund,	Shareholder	May 01 '26	Proposed Sale	0.72	79,549	57,243		May 01 04:51 PM
MPM Asset Management LLC	Shareholder	May 01 '26	Proposed Sale	0.72	57,588	41,440		May 01 04:51 PM
EVNIN LUKE	Director	Apr 28 '26	Sale	0.73	95,412	69,651	2,010,508	Apr 29 07:16 PM
EVNIN LUKE	Director	Apr 27 '26	Sale	0.85	53,940	45,849	2,105,920	Apr 29 07:16 PM
EVNIN LUKE	Director	Apr 29 '26	Sale	0.69	56,559	39,026	1,953,949	Apr 29 07:16 PM
MPM Asset Management LLC	Shareholder	Apr 29 '26	Proposed Sale	0.74	20,608	15,250		Apr 29 04:48 PM
MPM Asset Management Investors	Shareholder	Apr 29 '26	Proposed Sale	0.74	4,479	3,314		Apr 29 04:48 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Apr 29 '26	Proposed Sale	0.74	107,652	79,662		Apr 29 04:48 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Apr 29 '26	Proposed Sale	0.74	8,678	6,422		Apr 29 04:47 PM
MPM BioVentures 2014, L.P.	Shareholder	Apr 29 '26	Proposed Sale	0.74	130,115	96,285		Apr 29 04:47 PM
MPM Oncology Innovations Fund,	Shareholder	Apr 29 '26	Proposed Sale	0.74	28,468	21,066		Apr 29 04:47 PM
MPM Asset Management LLC	Shareholder	Apr 27 '26	Proposed Sale	0.81	20,608	16,754		Apr 27 05:01 PM
MPM Asset Management Investors	Shareholder	Apr 27 '26	Proposed Sale	0.81	4,479	3,641		Apr 27 05:01 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Apr 27 '26	Proposed Sale	0.81	8,678	7,055		Apr 27 05:00 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Apr 27 '26	Proposed Sale	0.81	107,652	87,521		Apr 27 05:00 PM
MPM BioVentures 2014, L.P.	Shareholder	Apr 27 '26	Proposed Sale	0.81	130,115	105,784		Apr 27 05:00 PM
MPM Oncology Innovations Fund,	Shareholder	Apr 27 '26	Proposed Sale	0.81	28,468	23,144		Apr 27 04:59 PM
EVNIN LUKE	Director	Jan 16 '26	Sale	0.54	38,782	20,942	2,159,860	Jan 20 04:07 PM
EVNIN LUKE	Director	Jan 13 '26	Sale	0.55	43,198	23,759	2,266,671	Jan 15 05:22 PM
EVNIN LUKE	Director	Jan 15 '26	Sale	0.55	37,413	20,577	2,198,642	Jan 15 05:22 PM
EVNIN LUKE	Director	Jan 14 '26	Sale	0.57	30,616	17,451	2,236,055	Jan 15 05:22 PM
EVNIN LUKE	Director	Jan 12 '26	Sale	0.57	58,980	33,619	2,309,869	Jan 12 05:09 PM
EVNIN LUKE	Director	Jan 09 '26	Sale	0.61	24,678	15,054	2,368,849	Jan 12 05:09 PM
EVNIN LUKE	Director	Jan 08 '26	Sale	0.63	7,716	4,861	2,393,527	Jan 12 05:09 PM
EVNIN LUKE	Director	Jan 06 '26	Sale	0.65	40,761	26,495	2,413,158	Jan 07 05:12 PM
EVNIN LUKE	Director	Jan 05 '26	Sale	0.64	18,378	11,762	2,453,919	Jan 07 05:12 PM
EVNIN LUKE	Director	Jan 07 '26	Sale	0.64	11,915	7,626	2,401,243	Jan 07 05:12 PM
MPM Asset Management LLC	Shareholder	Jan 06 '26	Proposed Sale	0.64	31,458	20,272		Jan 06 04:59 PM
MPM Asset Management Investors	Shareholder	Jan 06 '26	Proposed Sale	0.64	6,840	4,408		Jan 06 04:58 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Jan 06 '26	Proposed Sale	0.64	13,256	8,542		Jan 06 04:57 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Jan 06 '26	Proposed Sale	0.64	164,126	105,763		Jan 06 04:56 PM
MPM BioVentures 2014, L.P.	Shareholder	Jan 06 '26	Proposed Sale	0.64	198,739	128,067		Jan 06 04:54 PM
MPM Oncology Innovations Fund,	Shareholder	Jan 06 '26	Proposed Sale	0.64	43,767	28,203		Jan 06 04:54 PM
EVNIN LUKE	Director	Dec 30 '25	Sale	0.61	34,847	21,257	2,515,827	Jan 02 05:32 PM
EVNIN LUKE	Director	Dec 31 '25	Sale	0.62	24,962	15,476	2,490,865	Jan 02 05:32 PM
EVNIN LUKE	Director	Jan 02 '26	Sale	0.63	18,568	11,698	2,472,297	Jan 02 05:32 PM
EVNIN LUKE	Director	Dec 29 '25	Sale	0.61	108,606	66,250	2,550,674	Dec 29 05:27 PM
EVNIN LUKE	Director	Dec 23 '25	Sale	0.63	71,428	45,000	2,711,222	Dec 29 05:27 PM
EVNIN LUKE	Director	Dec 22 '25	Sale	0.69	59,307	40,922	2,782,650	Dec 29 05:27 PM
EVNIN LUKE	Director	Dec 26 '25	Sale	0.63	35,632	22,448	2,659,280	Dec 29 05:27 PM
EVNIN LUKE	Director	Dec 24 '25	Sale	0.65	16,310	10,602	2,694,912	Dec 29 05:27 PM
MPM Asset Management Investors	Shareholder	Dec 29 '25	Proposed Sale	0.65	4,479	2,931		Dec 29 04:48 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Dec 29 '25	Proposed Sale	0.65	107,463	70,313		Dec 29 04:47 PM
MPM Oncology Innovations Fund,	Shareholder	Dec 29 '25	Proposed Sale	0.65	28,657	18,750		Dec 29 04:47 PM
MPM BioVentures 2014, L.P.	Shareholder	Dec 29 '25	Proposed Sale	0.65	130,125	85,141		Dec 29 04:46 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Dec 29 '25	Proposed Sale	0.65	8,679	5,679		Dec 29 04:45 PM
MPM Asset Management LLC	Shareholder	Dec 29 '25	Proposed Sale	0.65	20,597	13,477		Dec 29 04:45 PM
MPM BioVentures 2014, L.P.	Shareholder	Dec 22 '25	Proposed Sale	0.69	130,125	89,370		Dec 22 04:57 PM
MPM Asset Management Investors	Shareholder	Dec 22 '25	Proposed Sale	0.69	4,479	3,076		Dec 22 04:57 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Dec 22 '25	Proposed Sale	0.69	107,463	73,806		Dec 22 04:56 PM
MPM Oncology Innovations Fund,	Shareholder	Dec 22 '25	Proposed Sale	0.69	28,657	19,682		Dec 22 04:56 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Dec 22 '25	Proposed Sale	0.69	8,679	5,961		Dec 22 04:56 PM
MPM Asset Management LLC	Shareholder	Dec 22 '25	Proposed Sale	0.69	20,597	14,146		Dec 22 04:55 PM
EVNIN LUKE	Director	Dec 15 '25	Sale	1.07	23,640	25,295	2,866,488	Dec 17 06:28 PM
EVNIN LUKE	Director	Dec 16 '25	Sale	1.05	14,548	15,275	2,851,940	Dec 17 06:28 PM
EVNIN LUKE	Director	Dec 17 '25	Sale	1.14	9,983	11,381	2,841,957	Dec 17 06:28 PM
EVNIN LUKE	Director	Dec 10 '25	Sale	1.06	37,104	39,330	2,935,995	Dec 12 05:32 PM
EVNIN LUKE	Director	Dec 11 '25	Sale	1.07	28,009	29,970	2,907,986	Dec 12 05:32 PM
EVNIN LUKE	Director	Dec 12 '25	Sale	1.08	17,858	19,287	2,890,128	Dec 12 05:32 PM
MPM Asset Management LLC	Shareholder	Dec 10 '25	Proposed Sale	1.01	14,029	14,169		Dec 10 05:05 PM
MPM Oncology Innovations Fund,	Shareholder	Dec 10 '25	Proposed Sale	1.01	19,519	19,714		Dec 10 05:04 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Dec 10 '25	Proposed Sale	1.01	73,195	73,927		Dec 10 05:03 PM
MPM Asset Management Investors	Shareholder	Dec 10 '25	Proposed Sale	1.01	3,050	3,080		Dec 10 05:02 PM
MPM BioVentures 2014, L.P.	Shareholder	Dec 10 '25	Proposed Sale	1.01	88,632	89,518		Dec 10 05:02 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Dec 10 '25	Proposed Sale	1.01	5,912	5,971		Dec 10 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HOWL

Werewolf Therapeutics Inc

Upgrade your Finviz experience